Transcriptomic profiles of endocrine-resistant breast cancer.

ABSTRACT:

Background

The majority of breast cancer patients have tumors expressing estrogen receptor α (ER) and are treated with adjuvant endocrine therapy. However, nearly one-third relapse, most with retained ER expression.

Methods

This study investigated patients with ER-positive and human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer. Patients with ER-positive relapses within five years of ongoing endocrine therapy were defined as endocrine-resistant (N = 69). Patients with no disease progression after 10 years were defined as endocrine-sensitive (N = 77). RNA was extracted from archived tumor blocks, followed by gene expression analysis.

Results

Significant differences were observed with higher tumor grades, intrinsic subtype risk scores, and upr

SUBMITTER: Schagerholm Stanev C 

PROVIDER: S-EPMC12516873 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature